Marinus Pharmaceuticals

MRNS · NASDAQ

Price unavailable right now.

No price history for this range.

MRNS analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 15, 2025

Bull case

Marinus Pharmaceuticals Inc. reported Ztalmy product sales of $8.5 million for Q3 2024, representing a significant increase of 56% year-over-year, highlighting robust growth in its marketed product for CDKL5 deficiency disorder. Furthermore, despite narrowing its FY24 net product revenue guidance to $33M-$34M, the company is focused on strategic alternatives to enhance shareholder value, which could include partnerships or sales that may unlock additional potential for its assets. The decrease in R&D expenses after completing the RAISE Trial suggests a more streamlined operational efficiency, which could support future investment in expanding Ztalmy's market presence and development of additional therapeutic opportunities.

Bear case

Marinus Pharmaceuticals Inc. has experienced a decline in SG&A expenses, falling 15.4% year-over-year to $12.6 million, which was below management's expectations of $14.9 million; however, this reduction does not compensate for the broader challenges. The company's guidance for full-year 2024 has been adjusted downwards to $33-34 million from prior estimates of $33-35 million, indicating modest patient additions and emphasizing the clinical risks associated with rare disease focus, particularly regarding patient recruitment delays. Additionally, management's observation that only one-third of patients showed robust responses, compared to expectations based on previous studies, coupled with anticipated dilution and challenges in patent extensions, suggests significant obstacles that may impede revenue growth and investor confidence, contributing to a negative outlook for the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.